Glovadalen Explained
Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson's disease.[1] [2] [3] [4] [5] [6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor by 10-fold in vitro with no actions on other dopamine receptors. As of May 2024, glovadalen is in phase 2 clinical trials for this indication. The drug is under development by UCB Biopharma. It is described as an orally active, centrally penetrant small molecule.
See also
Notes and References
- Web site: UCB 0022 . AdisInsight . Springer Nature Switzerland AG . 28 May 2024 . 10 August 2024.
- Web site: Delving into the Latest Updates on Glovadalen with Synapse . Synapse . 8 August 2024 . 10 August 2024.
- McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, Wyse RK, Stott SR . Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update . Journal of Parkinson's Disease . 13 . 4 . 427–439 . 2023 . 37302040 . 10357160 . 10.3233/JPD-239901 . Our analysis of dopaminergic therapies shows a continued emphasis on DA agonists and levodopa reformulation. These include Cerevel's tavapadon, a D1/D5 receptor partial agonist and UCB0022, a positive allosteric modulator of the D1 receptor, as well as approaches to sub-cutaneously deliver levodopa/carbidopa such as Abbvie's ABBV-951 and Neuroderm's ND0612. .
- Web site: Glovadalen . IUPHAR/BPS Guide to PHARMACOLOGY . 10 August 2024.
- Web site: UCB0022 . ALZFORUM . 3 May 2024 . 10 August 2024.
- Vermeiren C, Ates A, Bouzom F, Delaunois A, Gillard M, Kenda B, Ousset A, Provins L, Skolc D, Valade A, Vanmeulder M, Wood M, Lamberty Y . Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM) . Movement Disorders . 37 . Suppl 2 [2022 International Congress September 15-18, 2022. Madrid, Spain] . 7 September 2022 . 10 August 2024.